The U.S. Food and Drug Administration authorized the use of a COVID-19 booster shot in children ages 5 to 11, even though data from the Centers for Disease Control and Prevention show case rates among kids in this age group who got two shots are now higher than rates in children who did not get the shots.
The U.S. Food and Drug Administration (FDA) amended its emergency use authorization for the Pfizer-BioNTech COVID-19 shot to allow a booster dose for children ages 5 to 11.
The FDA’s “evaluation of safety” for the booster dose in young children was based on a study of only about 400 children, and no meeting was held with the Vaccines and Related Biological Products Advisory Committee.
The booster shot is intended to be given at least five months after the primary two-dose series has been completed, but less than one-third — only 28.8% — of U.S. children in this age group have received the first two doses of this experimental gene therapy.
“[G]iven that these children have the lowest coronavirus vaccination rate of all eligible Americans, [as most parents have wisely avoided giving their child the jab] public health experts are not expecting a rush for the booster,” The New York Times reported, and this is good news since multiple red flags have arisen regarding the use of these shots, particularly among children.
COVID shots’ dismal effectiveness wanes rapidly
Booster shots are typically released because the initial shots aren’t working as planned.
This is certainly the case with COVID-19 shots, which have been found to have dismally low effectiveness rates of 12%, according to research conducted by the New York State Department of Health.
Read More: More COVID Cases in Kids Who Got 2 Shots Compared to Those Who Got None, CDC Reports